- Home
- TACT vs ACHL Comparison
TACT vs ACHL Comparison
Compare TACT & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- ACHL
- Stock Information
- Founded
- TACT 1996
- ACHL 2016
- Country
- TACT United States
- ACHL United Kingdom
- Employees
- TACT N/A
- ACHL N/A
- Industry
- TACT Computer peripheral equipment
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TACT Technology
- ACHL Health Care
- Exchange
- TACT Nasdaq
- ACHL Nasdaq
- Market Cap
- TACT 40.6M
- ACHL 43.6M
- IPO Year
- TACT 1996
- ACHL 2021
- Fundamental
- Price
- TACT $3.97
- ACHL $0.98
- Analyst Decision
- TACT Strong Buy
- ACHL Buy
- Analyst Count
- TACT 1
- ACHL 2
- Target Price
- TACT $7.50
- ACHL $4.00
- AVG Volume (30 Days)
- TACT 20.5K
- ACHL 128.3K
- Earning Date
- TACT 11-07-2024
- ACHL 11-14-2024
- Dividend Yield
- TACT N/A
- ACHL N/A
- EPS Growth
- TACT N/A
- ACHL N/A
- EPS
- TACT N/A
- ACHL N/A
- Revenue
- TACT $46,418,000.00
- ACHL N/A
- Revenue This Year
- TACT N/A
- ACHL N/A
- Revenue Next Year
- TACT $16.86
- ACHL N/A
- P/E Ratio
- TACT N/A
- ACHL N/A
- Revenue Growth
- TACT N/A
- ACHL N/A
- 52 Week Low
- TACT $3.32
- ACHL $0.63
- 52 Week High
- TACT $7.97
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- TACT 41.94
- ACHL 36.56
- Support Level
- TACT $3.94
- ACHL $0.92
- Resistance Level
- TACT $4.11
- ACHL $1.01
- Average True Range (ATR)
- TACT 0.18
- ACHL 0.04
- MACD
- TACT -0.02
- ACHL -0.01
- Stochastic Oscillator
- TACT 24.32
- ACHL 37.41
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.